Compare McKesson Corporation (MCK) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Vistra Corp — how do they compare? McKesson Corporation trades at $829.3 (market cap $97.35B), while Vistra Corp trades at $160.79 (market cap $53.27B). The key difference: McKesson Corporation is the larger of the two by market cap, and Vistra Corp pays the higher dividend (0.58%). Which is the better fit depends on your goals.
| MCK | VST | |
|---|---|---|
Market Cap | $97.35B | $53.27B |
Sector | Health | Technology |
52-Week High | $995.69 | $217.92 |
52-Week Low | $659.01 | $134.71 |
Enterprise Value | $101.98B | $75.03B |
Dividend Yield | 0.39% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Vistra Corp (VST) trades at $157.99, up 1.64% today, showing mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported strong Q1 2026 earnings beat ($2.87 vs $1.32 expected) after previous misses, with 2026 revenue projected at $19.4B and net profit margin improving to 11.52%. Recent news highlights Vistra's positioning as a potential beneficiary of AI-driven power demand growth.
Wall Street maintains strong bullish sentiment with 91% buy ratings and a $253 consensus price target representing 60% upside potential. Key risks include power price volatility, high debt levels, and project execution challenges. The company's long-term power purchase agreements with major tech firms provide revenue visibility, but investors should monitor Q2 2026 earnings due August 7th for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
